

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



February 6, 2025

Company name: TAUNS Laboratories, Inc.
Representative: Masaki Nonaka, President and CEO
(Code no.: 197A, Standard Market, Tokyo Stock Exchange)
Contact person: Yoshio Uchiyama, Director and CFO
Tel: +81-55-957-3090

Notice of Strategic Business Alliance with ZACROS Corporation

We are pleased to announce that as of today, we have entered into Business Alliance Agreement with ZACROS Corporation (Representative Director and President: Taku Shimoda, hereinafter “ZACROS”) for the development and manufacture of components for POCT(*1) devices.

(*1) POCT: Abbreviation for “Point of Care Testing”. Immediate testing at the clinical site performed by medical staff at or near the side of patient.

As one of the major companies of rapid diagnostic test kits for infectious diseases in Japan, we manufacture and sell in vitro diagnostics / antigen test kits that are widely used in medical institutions both in Japan and overseas. We have achieved high sensitivity in immunochromatography using our proprietary “platinum-gold colloids” nanotechnology, and as a medium- to long-term strategy, we are working to expand our business into the chronic disease and prevention/sub-health fields, as well as to develop new diagnostic technologies and next-generation POCTs, while expanding our lineup of antigen test kits.

ZACROS, on the other hand, is a company with a long business history in the pharmaceutical and medical packaging industry, with a sophisticated quality control system and film processing technology developed over many years. In recent years, the company has focused on the area where plastic and biotechnology intersect, offering products such as “BioPhaS”, custom-order service for single-use bag and related products for the manufacturing of biopharmaceuticals and other products, “T-TAS” (Total Thrombus-formation Analysis System), a medical device, and a microchip with multiple microfluidic channels (biochips) containing proteins and reagents. In October 2024, the company changed its name from Fujimori Kogyo Co., Ltd. on the occasion of its 110th anniversary.

Under this strategic business alliance, we will utilize ZACROS' biochip technology in our next-generation POCT device we are developing, and work to develop innovative diagnostic products for the global market. Through this alliance, we expect to improve the functionality and expand the application range of our next-generation POCT device, while ZACROS expects to gain important adoption results for its biochip business. At the same time, this alliance will also include joint development to improve the production efficiency and quality of our current rapid diagnostic kits for infectious diseases.

This matter will have no impact on our company's performance at this time. If it is found to have a significant impact, we will disclose it promptly.

Regarding this alliance, Mr. Nonaka, President and CEO of our company, and Mr. Shimoda, Representative Director and President, ZACROS Corporation, made the following comments.

Message from Masaki Nonaka, President and CEO, TAUNS Laboratories, Inc.

“We are very pleased that ZACROS has evaluated and agreed with our company's aim of achieving the advanced testing, which is currently performed in laboratories, through POCT, and that we will be able to carry out joint development. Through this partnership, we aim to contribute to the efficiency of medical care by enhancing the functionality of POCT.”

Message from Taku Shimoda, Representative Director and President, ZACROS Corporation

“We are very pleased that TAUNS Laboratories, Inc. has evaluated and will utilize the technology of biochips, an area in which our company is focusing its efforts on the fusion of plastics and biotechnology. Through this partnership, we hope to create next-generation POCT solutions that do not yet exist in the world, and improve the convenience of medical professionals and patients around the world.”

【About TAUNS Laboratories, Inc.】

TAUNS Laboratories, Inc. is a research and development-oriented manufacturer with strengths in diagnostic technology, founded in Numazu City, Shizuoka Prefecture, in 1987. With the corporate slogan “Peace of mind through diagnostic technology,” the company has been providing the world with antigen test kits that utilize its many years of expertise in the field of respiratory infections.

《<https://www.tauns.co.jp/>》

【About ZACROS Corporation】

Since its establishment in 1914, ZACROS Corporation has expanded its business into a wide range of fields, including packaging materials for daily necessities and pharmaceutical and medical products, contract cell culture service, electronic materials, and industrial infrastructure, based on its core technologies of film lamination and coating.

《<https://www.zacros.co.jp/>》

The purpose of this release is to provide our stakeholders with the latest information related to our companies. Although it may contain information on our products and research and development, it is intended to disclose our management information and is not intended as promotion, advertisement, or medical advice regarding our products.

【For inquiries regarding this matter】

TAUNS Laboratories, Inc.

General Affairs Department

TEL: 055-957-3090

E-mail: web@tauns.co.jp

ZACROS Corporation

Corporate Branding Group

URL: <https://www.zacros.co.jp/en/contact/>